Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001683168-25-002998
Filing Date
2025-04-30
Accepted
2025-04-30 16:30:10
Documents
19
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K cns_10ka1-123124.htm   iXBRL 10-K/A 245833
2 CERTIFICATION cns_ex3101.htm EX-31.1 3542
3 CERTIFICATION cns_ex3102.htm EX-31.2 3463
  Complete submission text file 0001683168-25-002998.txt   709681

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cnsp-20241231.xsd EX-101.SCH 3600
5 XBRL DEFINITION FILE cnsp-20241231_def.xml EX-101.DEF 6241
6 XBRL LABEL FILE cnsp-20241231_lab.xml EX-101.LAB 97138
7 XBRL PRESENTATION FILE cnsp-20241231_pre.xml EX-101.PRE 69899
22 EXTRACTED XBRL INSTANCE DOCUMENT cns_10ka1-123124_htm.xml XML 7479
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39126 | Film No.: 25895906
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)